These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1893057)

  • 1. Hydration of fibrinogen, fibrin, and fibrin degradation product (FDP) as estimated by nuclear magnetic resonance (NMR) spectroscopy.
    Tanaka Y; Nakaya S; Yoshioka Y; Yoshida Y; Hanaoka H; Kawamura R; Yasuda N
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):243-9. PubMed ID: 1893057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracking oxidation-induced alterations in fibrin clot formation by NMR-based methods.
    Lau WH; White NJ; Yeo TW; Gruen RL; Pervushin K
    Sci Rep; 2021 Aug; 11(1):15691. PubMed ID: 34344919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of conformational domain lability of fibrinogen molecule in the processes of fibrin formation and fibrinolysis.
    Rozenfel'd MA; Leonova VB; Biryukova MI
    Dokl Biochem Biophys; 2006; 408():165-8. PubMed ID: 16913421
    [No Abstract]   [Full Text] [Related]  

  • 4. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
    Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
    J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics of D-domain-containing specific inhibitors of polymerization on the fibrin self-assembly process].
    Platonova TM; Chernyshenko TM; Sokolovs'ka LI
    Ukr Biokhim Zh (1999); 2006; 78(3):124-9. PubMed ID: 17100320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure of soluble fibrin oligomers.
    Rosenfeld MA; Leonova VB; Biryukova MI; Vasileva MV
    Dokl Biochem Biophys; 2011; 440():203-6. PubMed ID: 22095118
    [No Abstract]   [Full Text] [Related]  

  • 7. Crystal structures of fragments D and double-D from fibrinogen and fibrin.
    Doolittle RF; Spraggon G; Everse SJ
    Thromb Haemost; 1999 Aug; 82(2):271-6. PubMed ID: 10605713
    [No Abstract]   [Full Text] [Related]  

  • 8. Unreliability of current serum fibrin degradation product (FDP) assays.
    Gaffney PJ; Perry MJ
    Thromb Haemost; 1985 Jun; 53(3):301-2. PubMed ID: 3901388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological behavior of higher molecular weight products of fibrinolysis.
    Chang ML; Bang NU
    J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of the fibrinogen-fibrin transformation: contributions from X-ray crystallography.
    Doolittle RF
    Blood Rev; 2003 Mar; 17(1):33-41. PubMed ID: 12490209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear magnetic resonance relaxation in experimental brain edema: effects of water concentration, protein concentration, and temperature.
    Kamman RL; Go KG; Brouwer W; Berendsen HJ
    Magn Reson Med; 1988 Mar; 6(3):265-74. PubMed ID: 3362061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton NMR study of the state of water in fibrin gels, plasma, and blood clots.
    Blinc A; Lahajnar G; Blinc R; Zidansek A; Sepe A
    Magn Reson Med; 1990 Apr; 14(1):105-22. PubMed ID: 2161980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
    Dyr JE; Cajthamlová H; Suttnar J
    Cas Lek Cesk; 1990 Oct; 129(43):1349-51. PubMed ID: 2249231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products.
    Connaghan DG; Francis CW; Ryan DH; Marder VJ
    Am J Clin Pathol; 1986 Sep; 86(3):304-10. PubMed ID: 3751995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of fibrin generation alterations in dogs with haemangiosarcoma using resonance thrombography.
    Mischke R; Wohlsein P; Schoon HA
    Thromb Res; 2005; 115(3):229-38. PubMed ID: 15617746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of D dimer in patients with elevated fibrinogen degradation products in serum: further study in chronic myelogenous leukemia.
    Saito M; Asakura H; Jokaji H; Uotanzi C; Kumabashiri I; Yoshida T; Hashizume K; Matsuda T
    Acta Haematol; 1990; 84(3):149-55. PubMed ID: 2123066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of end products of plasmin-mediated hydrolysis of fibrinogen and fibrin (EF and Ef fragments) on fibrinogen cross-linking].
    Leonova VB; Rozenfel'd MA; Biriukova MI; Kostanova EA; Vasil'eva MV
    Izv Akad Nauk Ser Biol; 2002; (5):522-7. PubMed ID: 12400374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products.
    Kogan AE; Mukharyamova KS; Bereznikova AV; Filatov VL; Koshkina EV; Bloshchitsyna MN; Katrukha AG
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):542-50. PubMed ID: 26656897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the effective correlation time modulating 1H NMR relaxation processes of bound water in protein solutions.
    Yilmaz A; Budak H; Ulak FS
    Magn Reson Imaging; 2008 Feb; 26(2):254-60. PubMed ID: 17683891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on fibrinogen, fibrin, and blood coagulation of proteolytic extracts from fruits of Pseudananas macrodontes, Bromelia balansae, and B. hieronymi (Bromeliaceae) in comparison with bromelain.
    Errasti ME; Prospitti A; Viana CA; Gonzalez MM; Ramos MV; Rotelli AE; Caffini NO
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):441-9. PubMed ID: 26886361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.